Trial Profile
Efficacy and Safety of Eslicarbazepine Acetate (BIA 2 093) in Acute Manic Episodes Associated With Bipolar I Disorder in a Double Blind, Randomised, Dose Titration, Placebo Controlled, Multicentre Clinical Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Jan 2022
Price :
$35
*
At a glance
- Drugs Eslicarbazepine acetate (Primary)
- Indications Bipolar I disorders
- Focus Therapeutic Use
- Sponsors Bial
- 03 May 2014 Tolerability results from a pooled analysis of 5 trials in elderly patients who participated in non-epilepsy studies presented at the 66th Annual Meeting of the American Academy of Neurology.
- 26 Sep 2013 Pooled analysis presented at the 21st World Congress of Neurology.
- 26 Sep 2013 Primary endpoint 'Young-Mania-Rating-Scale' has not been met.